CLINICAL TRIALS PROFILE FOR SAXAGLIPTIN
✉ Email this page to a colleague
All Clinical Trials for SAXAGLIPTIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00121641 ↗ | Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise | Completed | AstraZeneca | Phase 3 | 2005-07-01 | The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise |
| NCT00121667 ↗ | Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone | Completed | AstraZeneca | Phase 3 | 2005-08-01 | The purpose of this clinical research study is to learn whether Saxagliptin added to Metformin therapy is more effective than Metformin alone as a treatment for type 2 diabetic subjects who are not sufficiently controlled with Metformin alone |
| NCT00295633 ↗ | A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone | Completed | AstraZeneca | Phase 3 | 2006-03-01 | The purpose of this clinical research study is to learn whether Saxagliptin added to thiazolidinedione (TZD) therapy is more effective than TZD alone as a treatment for Type 2 diabetic subjects who are not sufficiently controlled with TZD alone |
| NCT00313313 ↗ | A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas | Completed | AstraZeneca | Phase 3 | 2006-04-01 | The purpose of this trial is to understand if adding saxagliptin to a sulfonylurea is safe and works better than increasing the amount of sulfonylurea a patient takes |
| NCT00316082 ↗ | Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise | Completed | AstraZeneca | Phase 3 | 2006-06-01 | The purpose of this trial is to understand if saxagliptin is more effective than placebo as a treatment for type 2 diabetic subjects who are not controlled with diet and exercise |
| NCT00327015 ↗ | A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise | Completed | AstraZeneca | Phase 3 | 2006-05-01 | The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe and works better than taking either saxagliptin or metformin alone |
| NCT00374907 ↗ | A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise | Completed | AstraZeneca | Phase 3 | 2006-09-01 | The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SAXAGLIPTIN
Condition Name
Clinical Trial Locations for SAXAGLIPTIN
Trials by Country
Clinical Trial Progress for SAXAGLIPTIN
Clinical Trial Phase
Clinical Trial Sponsors for SAXAGLIPTIN
Sponsor Name
